Author

Asher Chanan-Khan

Observed names: A Chanan-Khan, A. A. A. Chanan-Khan, A. Chanan-Khan

Institutions: Mayo Clinic, Mayo Clinic in Florida

Observed institutions: Roswell Park Comprehensive Cancer Center, City Of Hope National Medical Center, Mayo Clinic, Memorial Sloan Kettering Cancer Center, Universidad de Salamanca, National and Kapodistrian University of Athens, Cornell University, Moffitt Cancer Center, Saint Vincent's Catholic Medical Center, Wilhelminen Hospital, City of Hope, Hospital Clínic de Barcelona, Dana-Farber Cancer Institute, Hôpital Saint-Louis, Mayo Clinic in Florida, Weill Cornell Medicine, Kosan Biosciences (United States), Winship Cancer Institute

OpenAlex ID: A5109989258

Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial

2021 · John C. Byrd, Peter Hillmen, et al. · Journal of Clinical Oncology · 672

Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group

2010 · Meletios A. Dimopoulos, Evangelos Terpos, et al. · Journal of Clinical Oncology · 415

Cancer- and Treatment-Related Anemia Clinical Practice Guidelines in Oncology

2005 · George M Rodgers, David Cella, et al. · Journal of the National Comprehensive Cancer Network · 62

Phase I study of lorvotuzumab mertansine (LM, IMGN901) in combination with lenalidomide (Len) and dexamethasone (Dex) in patients with CD56-positive relapsed or relapsed/refractory multiple myeloma (MM).

2011 · J. G. Berdeja, S. Ailawadhi, et al. · Journal of Clinical Oncology · 35

Phase 1 clinical trial of KOS-953 + bortezomib (BZ) in relapsed refractory multiple myeloma (MM)

2006 · A. Chanan-Khan, P. Richardson, et al. · Journal of Clinical Oncology · 11

A264 Phase I Study of Elotuzumab (HuLuc63) in Combination with Bortezomib in Relapsed Multiple Myeloma

2009 · AJ Jakubowiak, W Bensinger, et al. · Clinical Lymphoma & Myeloma · 2

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Mayo Clinic Systematic Management and Risk-Adapted Therapy for Lymphoid Malignancies (lySMART) Consensus Guidelines 2026

2026 · Sameer A. Parikh, Paul J. Hampel, et al. · Mayo Clinic Proceedings · 1

POSTER: IBCL-291: Patterns of Treatment Utilization and Sequencing Across Lines of Therapy inWaldenström Macroglobulinemia: Real-World Evidence From the United States

2026 · Jorge J Castillo, Sheeba Koshy Thomas, et al. · Clinical Lymphoma Myeloma & Leukemia

IBCL-291: Patterns of Treatment Utilization and Sequencing Across Lines of Therapy in Waldenström Macroglobulinemia: Real-World Evidence From the United States

2026 · Jorge J Castillo, Sheeba Koshy Thomas, et al. · Clinical Lymphoma Myeloma & Leukemia

Supplementary Files from Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia

2026 · Alak Manna, Sonikpreet Aulakh, et al.

Data from Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia

2026 · Alak Manna, Sonikpreet Aulakh, et al.

POSTER: MM-718 Lisaftoclax (APG-2575) Combined With Novel Therapeutic Regimens in Patients With Relapsed or Refractory (R/R) Multiple Myeloma (MM) or Immunoglobulin Light-Chain (AL) Amyloidosis

2025 · Sikander Ailawadhi, Asher Chanan-Khan, et al. · Clinical Lymphoma Myeloma & Leukemia

MM-718: Lisaftoclax (APG-2575) Combined With Novel Therapeutic Regimens in Patients With Relapsed or Refractory (R/R) Multiple Myeloma (MM) or Immunoglobulin Light-Chain (AL) Amyloidosis

2025 · Sikander Ailawadhi, Asher Chanan-Khan, et al. · Clinical Lymphoma Myeloma & Leukemia

Works count: 13

Citation count: 1,197

H-index: 5

I10-index: 5